Bristol-Myers Squibb Co vs Harley-Davidson Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.66 (market cap $129.94B), while Harley-Davidson Inc trades at $26.91 (market cap $2.78B). The key difference: Bristol-Myers Squibb Co is far larger — about 46.7× Harley-Davidson Inc's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | HOG | |
|---|---|---|
Market Cap | $129.94B | $2.78B |
Sector | Health | Consumer Cyclical |
52-Week High | $65.89 | $31.03 |
52-Week Low | $42.60 | $17.19 |
Enterprise Value | $163.92B | $3.19B |
Dividend Yield | 3.96% | 2.75% |
Trailing returns across standard periods
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →